TITLE

Canada finally begins long journey to an HIV vaccine

AUTHOR(S)
Silversides, Ann
PUB. DATE
June 2004
SOURCE
CMAJ: Canadian Medical Association Journal;6/8/2004, Vol. 170 Issue 12, p1777
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Focuses on the therapeutic HIV vaccine trial launched by Canadian academics in Montréal, Quebec and Ottawa, Ontario. Sources of funding for the trial; Challenges in conducting trials of HIV vaccines; Features of the combination vaccine to be tested in the trial.
ACCESSION #
13258269

 

Related Articles

  • Definition of the viral targets of protective HIV-1-specific T cell responses.  // Journal of Translational Medicine;2011, Vol. 9 Issue 1, p208 

    The article offers information on the efficacy of the CTL component of future HIV-1 vaccine will depend on the induction of responses with the most potent antiviral activity and broad HLA class I restriction. Information regarding the current HIV vaccine designs that are largely based on viral...

  • Preparing for PrEP. ROEHR, BOB // Windy City Times;8/31/2011, Vol. 26 Issue 47, p17 

    The article provides information on pre-exposure prophylaxis (PrEP), and explores its potential in helping to rein in the number of new human immunodeficiency virus (HIV) infections that occur each year.

  • Estimating the Demand for a Preventive HIV Vaccine: Why We Need to Do Better. Hecht, Robert; Suraratdecha, Chutima // PLoS Medicine;Oct2006, Vol. 3 Issue 10, p1728 

    The article estimates the demand for a preventive human immunodeficiency virus (HIV) vaccine. A standardized and up-to-date profile of these hypothetical first-generation HIV vaccines, based on the latest scientific knowledge, would help to generate the most policy-relevant and comparable...

  • National HIV Vaccine Awareness Day.  // Tennessee Tribune;5/13/2010, Vol. 21 Issue 19, p5B 

    The article highlights the National HIV Vaccine Awareness Day as an opportunity to reflect on one's progress, renew one's commitment to finding an HIV vaccine and to personally thank the scientists and volunteers for this important strive in Bethesda, Maryland.

  • Two Double-Blinded, Randomized, Comparative Trials of 4 Human Immunodeficiency Virus Type 1... Schooley, Robert T.; Spino, Cathie; Kuritzkes, Daniel; Walker, Bruce D.; Valentine, Fred T.; Hirsch, Martin S.; Cooney, Elizabeth; Friedland, Gerald; Kundu, Smriti; Merigan Jr., Thomas C.; McElrath, M. Juliana; Collier, Ann; Plaeger, Susan; Mitsuyasu, Ronald; Khan, James; Haslett, Patrick; Uherova, Patricia; deGruttola, Victor; Chiu, Simon // Journal of Infectious Diseases;11/1/2000, Vol. 182 Issue 5, p1357 

    Presents two double-blinded, randomized, comparative trials of four HIV-1 envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity. Control of viral replication in vivo; Definition of patient populations most likely to respond to vaccination; Lymphoproliferative...

  • Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans. Pine, Samuel O.; Kublin, James G.; Hammer, Scott M.; Borgerding, Joleen; Yunda Huang; Casimiro, Danilo R.; McElrath, M. Juliana // PLoS ONE;2011, Vol. 6 Issue 4, p1 

    The results of the recent Step Study highlight a need to clarify the effects of pre-existing natural immunity to a vaccine vector on vaccine-induced T-cell responses. To investigate this interaction, we examined the relationship between preexisting Ad5 immunity and T-cell cytokine response...

  • AIDS vaccine flop.  // New Scientist;9/11/2004, Vol. 183 Issue 2464, p5 

    The article presents information on the results of an AIDS vaccine development. Trials of a combination of two promising AIDS vaccine candidates in Kenya, Uganda and Great Britain have produced disappointing results. Like nearly all of the 30 or so vaccines that have been tested in people, the...

  • Towards an HIV Vaccine. STRATOV, IVAN; KENT, STEPHEN // Australasian Science;Nov2011, Vol. 32 Issue 9, p30 

    The article reports on the latest developments in the efforts to find an effective vaccine against human immunodeficiency virus (HIV) as of November 2011. It cites that HIV is said to cause the acquired immune deficiency syndrome (AIDS). It presents the highly active anti-retroviral therapy...

  • HIV vaccine controversy. Jayaraman, K. S. // Nature Biotechnology;Mar2008, Vol. 26 Issue 3, p256 

    The article reports on the denial of the New York-based International AIDS Vaccine Initiative (IAVI) that it violated ethics by testing a US-made HIV vaccine in India. According to the author, the tgAAC09 vaccine uses an adeno-associated viral vector and has been developed by Targeted Genetics...

  • Taking an Alternative Approach to HIV Vaccination.  // PLoS Medicine;Jan2006, Vol. 3 Issue 1, pe58 

    The article presents information on a study by Xiao-Tong Song, Si-Yi Chen and colleagues on an alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. The researchers suggest that a molecule that helps regulate dendritic...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics